Honarvar Mohammad, Lobo Julio, Schneider Caitlin, Klein Samuel, Smith Gordon I, Loomba Rohit, Ramji Alnoor, Hassanein Tarek, Yoshida Eric M, Pang Emily, Curry Michael P, Afdhal Nezam H
Sonic Incytes Medical Corp. Vancouver, BC, Canada.
Washington University, School of Medicine, St. Louis, MO, USA.
WFUMB Ultrasound Open. 2024 Dec;2(2). doi: 10.1016/j.wfumbo.2024.100061. Epub 2024 Jul 26.
As prevalence of patients with steatotic liver diseases increases throughout the world, it is necessary to have accurate and accessible methods to estimate liver fat content. Using quantitative ultrasound parameters, such as attenuation and backscatter, it is possible to estimate liver fat, with MRI proton density fat fraction as the reference standard. Velacur determined fat fraction (VDFF) is a new output measurement on Velacur (Sonic Incytes Medical Corp, Vancouver, BC).
This study described the results of parameter fitting and validation of VDFF, which is a combination of quantitative ultrasound parameters. Patients were recruited from sites within the US and Canada. All patients had contemporaneous Velacur and MRI proton density fat fraction scans. The quantitative ultrasound parameter fitting was completed using linear regression on a random sub-sample approach, and a separate cohort was used for validation. The AUC for detection of 5% liver fat based on MRI-PDFF and the correlation between MRI-PDFF and VDFF was measured in both cohorts.
VDFF had an AUROC of 0.97 for the detection of MRI-PDFF > 5% in the parameter fitting cohort, and 0.99 in the validation cohort. The correlation [95% CI] between MRI-PDFF and VDFF was r = 0.84 [0.78 - 0.89] for the parameter fitting cohort and r = 0.90 [0.82 - 0.95] for the validation cohort.
The Velacur Determined Fat Fraction (VDFF) is an accurate and accessible way to estimate steatosis as measured by MRI-PDFF. Velacur VDFF can fill the unmet need of an accurate means to diagnosis hepatic steatosis and serve as a potential alternative to biopsy or MRI-PDFF.
随着脂肪性肝病患者在全球的患病率不断上升，有必要采用准确且可及的方法来估计肝脏脂肪含量。利用定量超声参数，如衰减和背向散射，以磁共振成像质子密度脂肪分数作为参考标准，就有可能估计肝脏脂肪。Velacur测定脂肪分数（VDFF）是Velacur（Sonic Incytes Medical Corp，温哥华，不列颠哥伦比亚省）的一项新的输出测量值。
本研究描述了VDFF（一种定量超声参数组合）的参数拟合和验证结果。患者从美国和加拿大的多个地点招募。所有患者均同时进行了Velacur和磁共振成像质子密度脂肪分数扫描。定量超声参数拟合采用随机子样本方法进行线性回归完成，并用一个单独的队列进行验证。在两个队列中均测量了基于磁共振成像质子密度脂肪分数检测5%肝脏脂肪的曲线下面积（AUC）以及磁共振成像质子密度脂肪分数与VDFF之间的相关性。
在参数拟合队列中，VDFF检测磁共振成像质子密度脂肪分数>5%的曲线下面积（AUROC）为0.97，在验证队列中为0.99。在参数拟合队列中，磁共振成像质子密度脂肪分数与VDFF之间的相关性[95%置信区间]为r = 0.84[0.78 - 0.89]，在验证队列中为r = 0.90[0.82 - 0.95]。
Velacur测定脂肪分数（VDFF）是一种准确且可及的方法，用于估计磁共振成像质子密度脂肪分数所测量的脂肪变性。Velacur VDFF可以满足准确诊断肝脂肪变性这一未被满足的需求，并可作为活检或磁共振成像质子密度脂肪分数的潜在替代方法。
